The FY2025 financial year was dynamic for the vaccine market and CSL Seqirus generated positive growth. Over the short term, two current trends will likely continue. First, the exciting acceleration of new vaccine technologies. CSL Seqirus is well positioned with its technology platforms (cell-based, adjuvants, and sa‑mRNA). The second trend is reduced rates of immunisation following the pandemic, particularly in the United States. However, the European vaccination market is stabilising. Against this backdrop, CSL Seqirus maintained commercial discipline in a competitive market. The business expects to continue to drive growth through life cycle management, which will allow CSL to deliver ongoing value to public health systems. Seasonal influenza remains one of the most consequential vaccine preventable diseases due to its significant morbidity and mortality, with unmet need across all populations, and with particular risk to the very young, due to immature immune systems and in older adults where immune systems start to wane over time. CSL Seqirus’ growth continues to be underpinned by its differentiated products – FLUAD® and FLUCELVAX® designed to help address these unmet needs. FLUAD® received preferential recommendation in Germany for people aged over 60 years. Additionally, CSL is advancing key development programs, including aTIVc with the goal of leading important innovation to further address the unmet need within the influenza vaccine space. CSL is also keen to bring the anticipated benefits of sa‑mRNA COVID vaccine to market. During FY2025, KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older, received regulatory approval from the European Commission and was launched by CSL’s partner in Japan. The CSL Seqirus strategy focuses on four key pillars: 1. C ontinue to grow the influenza franchise, further evolving its portfolio to innovative differentiated products that address unmet public health needs. 2. C ontinue to build on influenza pandemic and pre‑pandemic leadership. Pandemic preparedness is a critical public health imperative and an important part of the CSL Seqirus business as it leverages core capabilities and unique partnerships with governments and other key stakeholders. T oday, CSL has more than 30 agreements with governments around the world where it is uniquely positioned to respond to an influenza pandemic. With CSL Seqirus’ ongoing investments to continually enhance manufacturing capabilities and network, development of CSL Seqirus’ sa‑mRNA platform, and the strong collaborations with governmental partners, CSL Seqirus is well positioned to respond to the public health need in the event of a pandemic. 3. B roaden global portfolio beyond influenza. CSL is excited about its self‑amplifying mRNA technology that CSL hopes will lead to the next generation COVID‑19 vaccine. 4. Continue to invest in manufacturing capabilities, platforms and partnerships to keep pace with the growing demand for cell‑based vaccines. Looking ahead, CSL Seqirus’ efforts are focused on finalising clinical work and regulatory submissions in major markets around the world, enabling commercial launches over the next one to three years. Over the longer timeframe, CSL’s strategy of differentiation and continuous innovation aims to protect ever‑growing communities around the world and clearly establish CSL’s leadership within the markets it serves. US$2,166m CSL Seqirus revenue 17 CSL Limited Annual Report 2024/25 + READ MORE AT INVESTORS.CSL.COM
RkJQdWJsaXNoZXIy MjE2NDg3